Triasima Portfolio Management inc. Sells 753 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Triasima Portfolio Management inc. decreased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 9.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 7,448 shares of the biotechnology company's stock after selling 753 shares during the period. Triasima Portfolio Management inc.'s holdings in Axon Enterprise were worth $3,917,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fourth Dimension Wealth LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC grew its holdings in shares of Axon Enterprise by 132.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new position in shares of Axon Enterprise during the 1st quarter worth approximately $32,000. Alpine Bank Wealth Management purchased a new position in shares of Axon Enterprise during the 1st quarter worth approximately $40,000. Finally, Elequin Capital LP purchased a new position in shares of Axon Enterprise during the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Performance

Axon Enterprise stock traded up $8.61 during trading on Friday, reaching $754.47. The company had a trading volume of 158,463 shares, compared to its average volume of 697,803. Axon Enterprise, Inc has a 52 week low of $279.02 and a 52 week high of $830.21. The firm's 50-day simple moving average is $762.11 and its 200 day simple moving average is $644.50. The firm has a market capitalization of $58.74 billion, a price-to-earnings ratio of 182.24, a price-to-earnings-growth ratio of 85.50 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same period last year, the firm earned $1.15 EPS. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of analyst reports. The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. boosted their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research report on Thursday. Barclays boosted their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the stock an "overweight" rating in a research note on Friday, July 11th. Finally, Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $763.75.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the sale, the director directly owned 17,740 shares of the company's stock, valued at $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Jennifer H. Mak sold 75 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total value of $57,885.75. Following the sale, the chief accounting officer directly owned 15,240 shares in the company, valued at approximately $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.